Tel: +44(0)20 7691 0984 Email: contact@transpharmation.co.uk Newsletter Sign Up
  • CEO Mark Duxon interviewed by The Pharma Letter on impact of Brexit on CROs...
  • Announcing new premises in Poland with a focus on neuropsychiatric disorders...
  • State-of-the-art premises opening this month at Discovery Park in Kent...
  • Newly published work in Frontiers in Psychiatry demonstrating
  • the effectiveness of a clinically relevant dose of ketamine...
  • Head to 2021 conferences page to see titles of abstracts...
 

PK/PD studies

Pharmacokinetic (PK) and Pharmacodynamic (PD) assays are the engine room for Lead Optimisation Drug Discovery.

With our combined years of extensive experience delivering programmes into preclinical development, we understand the need for robust, pharmacologically sensitive, high-throughput, multi-modal in-vivo and ex-vivo endpoints that can be put into context with drug exposure levels.

We can offer almost any dosing route and preclinical species that you might require along with a broad range of behavioural end points and tissue / fluid collection capabilities.

Examples include:


pkThis list is not exhaustive, we are always developing new areas of discovery within our preclinical field of expertise. If there is something particular that is not listed here please do contact us.

Start a Conversation

uk flag +44 (0)20 7691 0984

ireland flag +353 (0)1896 42 60

poland flag +48 515 244 120

mail contact@transpharmation.co.uk


Copyright

Copyright © 2021 Transpharmation Ltd. All Rights Reserved.

Copyright © 2019 Transpharmation Ltd. All Rights Reserved. Website created by Identity Ipswich Web Design